Geron Corp (GERN): Operating Income
-$68.58M
Year ended 2025-12-31
-$51.77M
Trailing 12 months to 2026-06-30
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$68.58M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$173.73M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$193.94M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$138.55M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | -$114.00M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$76.91M | n/m | 2023-03-16, From 2020-01-01 |
| 2019-12-31 | -$72.50M | n/m | 2022-03-10, From 2019-01-01 |
| 2018-12-31 | -$31.07M | n/m | 2021-03-11, From 2018-01-01 |
| 2017-12-31 | -$29.25M | n/m | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | -$30.65M | n/m | 2019-03-07, From 2016-01-01 |
| 2015-12-31 | -$559.0K | n/m | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | -$36.31M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$38.96M | n/m | 2016-03-10, From 2013-01-01 |
| 2012-12-31 | -$71.76M | n/m | 2015-03-11, From 2012-01-01 |
| 2011-12-31 | -$96.12M | n/m | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | -$111.17M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$70.23M | n/a | 2012-03-07, From 2009-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| Geron Corp (GERN) | 2025-12-31 | -$68.58M | n/m |
| Standard Biotools Inc. (LAB) | 2025-12-31 | -$110.25M | n/m |
| Edgewise Therapeutics, Inc. (EWTX) | 2025-12-31 | -$191.41M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$213.06M | n/m |
| Septerna, Inc. (SEPN) | 2025-12-31 | -$68.30M | n/m |
| Organogenesis Holdings Inc. (ORGO) | 2025-12-31 | $44.69M | n/m |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | -$62.82M | n/m |
| Olema Pharmaceuticals, Inc. (OLMA) | 2025-12-31 | -$178.70M | n/m |
| Dianthus Therapeutics, Inc. (DNTH) | 2025-12-31 | -$177.93M | n/m |
Compare GERN, LAB, EWTX, NUVB side by side · Screen every company in Pharmaceutical Preparations ↗